AACR 2026 CD39 Blockade Shows Potential in Early-Stage Lung Cancer A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results